Leadership

Management Team

•  
  • Samuel Holtzman
  • , PhD
  • Cofounder, Chairman, President, and CEO
  • Founder and former Chairman, President, and CEO of Entelos, the world’s in silico biosimulation leader. Former partner at Strategic Decisions Group, specializing in pharmaceutical strategy and decision systems. Author of a book and several book chapters and many papers. Consulting Associate Professor in the Management Science and Engineering Department at Stanford University. PhD, Stanford; EE, SM & SB, M.I.T.
•  
  • Ron Beaver
  • , PhD
  • Cofounder, Executive Vice President, and CFO
  • Cofounder and former Managing Director of the consulting practice at Pharsight Corporation, the biopharmaceutical industry’s first combined CATD/strategic analysis practice. Cofounder and leader of the Pope Street Group, a strategic management consultancy and venture incubator. Former Associate at Strategic Decisions Group. PhD, Stanford; BA, Iowa State University/Simpson College.
•  
  • Rebecca A. Baillie
  • , PhD
  • Chief Scientist, PhysioPD
  • Former Scientist at Entelos, leading developer of Adipocyte PhysioLab™. 25 years’ basic research, drug discovery, and biomarker development in metabolism, diabetes, obesity, and lipid biochemistry. Experienced in large- and small-scale physiologic models and simulation for drug discovery, drug development, and biomarker research. PhD, University of Iowa; MS & BS, UC Davis.
•  
  • James R. Bosley, Jr
  • , PhD, PE
  • Principal
  • Former Senior Director of Product Management, Pharsight Corporation. 20 years’ experience executing and managing mathematical modeling projects for biotechnology, chemical, disease pathophysiology and drug disposition processes. Senior technology/project management positions with Entelos, Fluor-Daniel, and DuPont Central Research. PhD, University of Texas; MS, University of California; BS, University of Wisconsin. Member of ASCPT.
•  
  • Richard Ho
  • , MD-PhD
  • Principal
  • Former Director of Disease Simulation at Johnson & Johnson Pharmaceutical Research & Development in La Jolla (San Diego), CA. 20 years’ experience in biomedical research with the last ten focused on physiologic modeling and systems biology. Drove the adoption of physiologic modeling approaches in J&J’s pharma sector to provide decision support for both small- and large-molecule R&D in diabetes, anemia, and asthma. Residency in Internal Medicine and Fellowship in Rheumatology, Yale; MD-PhD, SUNY Buffalo; AB, Harvard; California medical license.
•  
  • Graham Jeffery
  • , MBA, CEng, CITP
  • Principal
  • Former Senior Engagement Manager at Strategic Decisions Group. Worked with several of the world’s leading pharmaceutical companies on asset and portfolio strategy. Helped develop industry-leading portfolio management methodology. Pioneered several advanced aspects of economic modeling technology. MBA, London Business School; MA, Jesus College, Cambridge; Chartered Engineer; Chartered IT Professional.

Board of Directors

•  
  • Samuel Holtzman
  • , PhD
  • Chairman
•  
  • Ron Beaver
  • , PhD
  • CFO

Advisory Board

•  
  • Wolfgang Greb
  • , MD, PhD
  • Founder and CEO, Focus Clinical Drug Development. Formerly VP, Worldwide Clinical Pharmacology, SmithKline Beecham Pharmaceuticals.
•  
  • Bernadette DeArmond
  • , MD
  • Founder and former President, Pacific Research Associates. Formerly Senior Vice President of Medical and Regulatory Affairs, ICON Clinical Research.